KEGG   DRUG: Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
Entry
D10755            Mixture   Drug                                   

Name
Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide;
Genvoya (TN)
Product
Component
Elvitegravir [DR:D06677], Cobicistat [DR:D09881], Emtricitabine [DR:D01199], (Tenofovir alafenamide fumarate [DR:D10605] | Tenofovir alafenamide [DR:D10428])
Remark
Therapeutic category: 6250
ATC code: J05AR18
Product: D10755<JP/US>
Efficacy
Antiviral
  Disease
HIV-1 infection [DS:H01563]
Comment
Elvitegravir and cobicistat are metabolized by CYP3A.
Cobicistat is also metabolized, to a minor extent, by CYP2D6.
Elvitegravir is a modest inducer of CYP2C9.
Cobicistat is an inhibitor of CYP3A and CYP2D6, and it is an inhibitor of the following transporters: P-gp, BCRP, OATP1B1 and OATP1B3. It is metabolized by OCT2.
Tenofovir alafenamide is a substrate of P-glycoprotein (P-gp) and CYP3A.
Target
HIV-1 integrase
RNA-directed DNA polymerase
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AR Antivirals for treatment of HIV infections, combinations
     J05AR18 Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat
      D10755  Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide <JP/US>
USP drug classification [BR:br08302]
 Antivirals
  Anti-HIV Combinations
   Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide Fumarate
    D10755  Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D10755  Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10755
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10755
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10755
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10755
Other DBs
PubChem: 273220351
ChEBI: 90922

» Japanese version   » Back

  All links  
Ontology (7)   
   KEGG BRITE (7)   
Disease (1)   
   KEGG DISEASE (1)   
Drug (1)   
   KEGG DGROUP (1)   
Chemical substance (2)   
   PubChem (1)   
   ChEBI (1)   
All databases (11)   

Download RDF
DBGET integrated database retrieval system